-
1 day ago | 
medscape.com | Megan Brooks
Adequate treatment of high blood pressure (BP) can substantially lower the risk for dementia or cognitive impairment without dementia, new data indicated. In a large study of Chinese adults with untreated hypertension, intensive BP management through medication and lifestyle changes cut the risk for dementia by 15% and cognitive impairment without dementia by 16% over 4 years.
-
1 day ago | 
deutsch.medscape.com | Megan Brooks
close Sind Sie sicher, dass Sie sich ausloggen wollen? Die Diagnose einer Demenz stellt Ärztinnen und Ärzte vor große Herausforderungen, medizinisch, aber auch kommunikativ. Ein neuer Leitfaden zeigt, wie sich Gespräche über kognitive Einschränkungen empathisch und individuell gestalten lassen – und wann Zurückhaltung angebracht ist [1].
-
3 days ago | 
medscape.com | Megan Brooks
Migraine with aura is the most prominent individual risk factor for unexplained stroke in adults younger than 50 years, particularly in women and in those with patent foramen ovale (PFO), a new study showed. While investigators found that both traditional and nontraditional risk factors contributed significantly to cryptogenic ischemic stroke (CIS) risk in young adults, there were notable differences depending on the presence of a clinically relevant PFO.
-
3 days ago | 
medscape.com | Megan Brooks
TOPLINE:A machine learning model trained on duodenal biopsy images achieves human pathologist-level performance in accurately diagnosed celiac disease (CD), with sensitivity and specificity above 95%. METHODOLOGY:There is a critical shortage of pathologists in developing and developed countries, often leading to long delays for patient diagnosis.
-
3 days ago | 
medscape.com | Megan Brooks
The US Food and Drug Administration (FDA) has granted 510(k) clearance to the Layer 7 Cortical Interface — a high-resolution cortical electrode array for use in recording, monitoring, and stimulating electrical activity on the surface of the brain. The array, from Precision Neuroscience Corporation, is a core component of the company’s fully implantable, wireless brain-computer interface (BCI) system, which is currently in development.
-
6 days ago | 
medscape.com | Megan Brooks
Incorporating a polygenic risk score into prostate cancer screening could enhance the detection of clinically significant prostate cancer that conventional screening may miss, according to results of the BARCODE 1 clinical trial conducted in the United Kingdom. The study found that about 72% of participants with high polygenic risk scores were diagnosed with clinically significant prostate cancers, which would not have been detected with prostate-specific antigen (PSA) testing or MRI.
-
1 week ago | 
medscape.com | Megan Brooks
New data show a significant uptick in depression among US adolescents and adults, with few receiving treatment. Depression is a leading cause of disability worldwide and has significant consequences for individual well-being and public health. The latest data from the National Health and Nutrition Examination Survey (NHANES), during 2021-2023, show that about 13% of individuals aged 12 years or older reported depression in the past 2 weeks — up from roughly 8% in 2013-2014.
-
1 week ago | 
medscape.com | Megan Brooks
Two early-stage clinical trials demonstrate the safety and potential effectiveness of stem cell therapies to treat Parkinson’s disease (PD), the second most common neurological disease worldwide. PD is characterized by the progressive loss of neurons that produce dopamine. Although current treatments, such as levodopa, can alleviate symptoms in the early stages of PD, their efficacy declines, and they are often accompanied by side effects such as dyskinesia.
-
1 week ago | 
espanol.medscape.com | Megan Brooks
Un esquema profiláctico mejorado con agentes ampliamente disponibles y fáciles de usar redujo significativamente la incidencia y la gravedad de las reacciones dermatológicas asociadas con amivantamab más lazertinib de primera línea en el cáncer de pulmón de células no pequeñas (CPCNP) avanzado con mutación del receptor del factor de crecimiento epidérmico (EGFR), según mostraron los primeros datos del ensayo COCOON.
-
1 week ago | 
espanol.medscape.com | Megan Brooks
Durante años, el tratamiento definitivo por default para pacientes con cáncer de pulmón de células no pequeñas (CPCNP) en estadio I temprano ha sido la resección quirúrgica, típicamente una lobectomía mínimamente invasiva con disección sistemática de ganglios linfáticos.[1] Las recomendaciones de la National Comprehensive Cancer Network (NCCN), la American Society of Clinical Oncology (ASCO) y la European Society for Medical Oncology (ESMO) indicaron la cirugía (en particular, la lobectomía)...
